Director Joseph Klein III of Ionis Pharmaceuticals Inc (NASDAQ: IONS) sold 21,332 shares of the company's common stock on March 3, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The sales, executed in multiple transactions, generated approximately $1.7 million, with trade prices reported between $79.174 and $80.818.
In the same filing, Klein disclosed exercising option awards to acquire an aggregate of 16,000 shares of Ionis stock. The exercised options carried strike prices of $40.05 and $42.88, representing a combined value of $652,120 at the exercise prices cited in the filing.
Following these dispositions and exercises, Klein's direct holdings stand at 11,014 shares of Ionis common stock. The SEC filing also notes a separate holding of 100 shares owned by Klein's son.
Market context
Ionis shares were trading at $75.16 at the time of the filing, below the levels at which Klein's recent sales executed but reflecting a reported 123% gain over the past year. The company is identified in the filing as a biotech with a market valuation cited at $12.4 billion, and analyst price targets mentioned in connection with the company span a wide range from $47 to $117.
Investor research access noted in the filing indicates that InvestingPro subscribers can view 11 additional tips on IONS and have access to Pro Research Reports covering over 1,400 U.S. equities.
Regulatory and clinical developments
Separately, Ionis announced that the U.S. Food and Drug Administration has accepted a supplemental New Drug Application for olezarsen under Priority Review, with a target action date of June 30, 2026. The filing states that the FDA's acceptance and Priority Review designation were based on results from the Phase 3 CORE and CORE2 studies.
Ionis is also scheduled to present new data on its hereditary angioedema therapy DAWNZERA at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting. The company said it will feature eight posters highlighting analyses from the Phase 3 OASIS-HAE and OASISplus studies.
Analyst activity
The filing and accompanying company disclosures note several analyst moves. Bernstein SocGen Group raised its price target on Ionis to $90, citing de-risking ahead of key Phase 3 readouts expected in the latter half of 2026. Stifel has increased its target to $77 despite Ionis’ 2026 topline guidance falling short of market expectations. Morgan Stanley lifted its target to $95, pointing to strong commercial execution in the fourth quarter of 2025 while noting that 2026 guidance was softer.
These developments depict a mixed but generally optimistic analyst view as Ionis advances regulatory milestones and late-stage clinical programs.
Takeaway
The filing documents significant insider sales and option exercises by a director while the company moves through regulatory review and prepares clinical data presentations. The transactions, analyst revisions, and upcoming FDA and congress presentations together form the near-term catalyst set for Ionis as it proceeds through 2026.